Hsu A, Liu Y, Zayac AS, et al. - Reports inscribe the correlation of SARS-CoV-2 infection with derangements in coagulation markers along with significant thrombotic complications and with postmortem detection of severe endothelial injury and widespread thrombotic microangiopathy in the pulmonary vasculature. Researchers here examined COVID-19 patients for the outcomes and laboratory trends following stratification by intensity of anticoagulation at time of admission. Between 27 February and 24 April 2020, hospitalization of 468 patients was reported. Patients with COVID-19 pneumonia had improved 30-day mortality in correlation with the use of high-intensity thromboprophylaxis (low molecular weight heparin 40 mg twice daily or unfractionated heparin 7500 units subcutaneous three times daily). Severe COVID-19 patients had significant increase in D-dimer level during hospitalization in correlation with receiving standard thromboprophylaxis but it remained stable or reduced with high-intensity prophylaxis or therapeutic anticoagulation, indicating the role of higher intensity anticoagulation in reducing adverse outcomes linked with COVID-19. No elevation in grade 3 or grade 4 bleeding events occur in patients with severe COVID-19 pneumonia in correlation with receiving high-intensity thromboprophylaxis or therapeutic anticoagulation (intravenous heparin, vitamin K antagonist, or direct oral anticoagulant) per the World Health Organization bleeding scale.